Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention | Zendy

Zuzana Moťovská | Zendy; Ota Hlinomaz | Zendy; Roman Miklík | Zendy; Milan Hromádka | Zendy; Ivo Varvařovský | Zendy; J Dušek | Zendy; Jiří Knot | Zendy; Jiří Jarkovský | Zendy; Petr Kala | Zendy; Richard Rokyta | Zendy; František Toušek | Zendy; P Kramarikova | Zendy; Bohumil Majtan | Zendy; Stanislav Simek | Zendy; M. Branny | Zendy; Jan Mrózek | Zendy; Pavel Červinka | Zendy; Jiří Ostřanský | Zendy; Petr Widimský | Zendy

Open Access

Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention

Author(s) -

Zuzana Moťovská,

Ota Hlinomaz,

Roman Miklík,

Milan Hromádka,

Ivo Varvařovský,

J Dušek,

Jiří Knot,

Jiří Jarkovský,

Petr Kala,

Richard Rokyta,

František Toušek,

P Kramarikova,

Bohumil Majtan,

Stanislav Simek,

M. Branny,

Jan Mrózek,

Pavel Červinka,

Jiří Ostřanský,

Petr Widimský

Publication year - 2016

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.116.024823

Subject(s) - medicine , prasugrel , ticagrelor , clopidogrel , myocardial infarction , percutaneous coronary intervention , cardiology , clinical endpoint , cardiogenic shock , stroke (engine) , randomized controlled trial , mechanical engineering , engineering

No randomized head-to-head comparison of the efficacy and safety of ticagrelor and prasugrel has been published in the 7 years since the higher efficacy of these newer P2Y 12 inhibitors were first demonstrated relative to clopidogrel.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research